Why biologics are different
- Residues may include proteins, host cell proteins, nucleic acids, process additives and product-related impurities.
- Endotoxin and bioburden risks may be more significant than conventional active residue alone.
- Biofilm risk requires operational control, hold-time management and effective cleaning frequency.
Shared-use challenges
- Multiple products and process matrices.
- Campaign manufacture and product changeover.
- Worst-case selection and matrixing justification.
- Balancing phase-appropriate validation with inspection-ready rationale.
Common mistakes
Common weaknesses include poorly justified limits, weak worst-case rationale, over-testing without risk logic, and failure to integrate routine operational controls into the validation strategy.
